Genzyme Tissue Repair - GZTR Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair - GZTR

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BWAC who wrote (203)	6/29/1999 9:37:00 PM
From: ajs	Read Replies (1) of 405

The PW midyear biotech review has GZTR as a buy with $8.00 12 month target (of course they thought it was worth $12-15 when it was selling for $8); GZTR has cash of $30 million and a market cap of less than $48 million. A few highlights from report: Carticel outlook improving has potential to be a $200-300 million product; Reduced expenditures from transfer of NeuroCell reduces burn $2-2.5 million per quarter; see $0.19 2001 fy EPS and $0.85 in 2002. IMO the value of Carticel alone should be at least 3 times sales so $6.00 per share today for Carticel if it were sold plus $1.50 in the bank in cash there is no way this dog is only worth $2.00. If GENZ can screw it up they probably will.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next